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Abstract
Rationale Several studies have suggested that modulation
of the glutamatergic system via metabotropic glutamate
receptors (mGlu) could be a new and efficient way to
achieve antipsychotic-like activity.
Objectives Here, we decided to investigate the possible role
of the group III mGlu receptor ligands, LSP1-2111, the
group III mGlu receptor orthosteric agonist, preferentially
stimulating mGlu4 receptors especially in low doses, and
AMN082, the mGlu7 receptor positive modulator. We used
MK-801- and amphetamine-induced hyperactivity tests, as
well as DOI-induced head twitches in mice as models for
positive symptoms of psychosis. The C57Bl/6J mGlu7
receptor knockout mice were used to confirm that
AMN082-induced effect was receptor specific. A non-
selective antagonist of the group II/III mGlu receptors,
LY341495, was used to block LSP1-2111-induced effects.
Results LSP1-2111 (1, 2, and 5 mg kg
−1) dose dependently
inhibited both MK-801- and amphetamine-induced hyper-
activities. Moreover, the drug antagonized DOI-induced
head twitches. The effects of the drug were antagonized by
LY341495 administration (1.5 mg kg
-1, i.p.). In contrast,
AMN082 (3 and 6 mg kg
−1) had no effect on amphetamine-
induced hyperactivity but induced an enhancement of MK-
801-induced hyperactivity and DOI-induced head twitches
in mice. In C57Bl/6J mGlu7 receptor knockout animals
(KO), those effects of AMN082 were not observed.
Moreover, mGlu7 KO animals were less sensitive for
DOI-induced effect than their wild type littermates.
Conclusions Altogether, we propose that among group III
mGlu receptors, mGlu4 receptor may be a promising target
for the development of novel antipsychotic drugs.
Keywords Schizophrenia.Metabotropic glutamate
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Amphetamine.Locomotor activity.Antipsychotics.
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Introduction
The glutamatergic theory of psychosis was raised in the
1987 (Javitt 1987) and was based on the behavioral data
indicating psychotomimetic properties of NMDA receptor
antagonists (e.g., phencyclidine), which induced positive,
negative, and cognitive abnormalities in animals, similar to
those observed in patients with psychosis (Javitt 1987;
Moghaddam 2004). As the hypofunction of the NMDA
receptor was shown to be responsible for psychotomimetic
effects, it became very plausible that positive modulation of
the receptor could be considered as a possible strategy for
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with the use of glycine, D-serine, or D-cycloserine (ligands
that act on the glycine modulatory site on the NMDA
receptor) showed that the compounds improved cognition
and decreased negative syndromes when co-administered
with commonly used neuroleptics (for review, see Coyle et
al. 2002).
Metabotropic glutamate receptors (mGlu) constitute a
natural alternative target to influence the glutamatergic
system. This is a family of eight proteins, divided into three
groups according to sequence homology, pharmacology, and
the second messenger system they activate (Pin and Duvoisin
1995). Thus, group I mGlu receptors constitute mGlu1 and
mGlu5 receptor subtypes, group II consists of mGlu2 and 3
receptors, while mGlu4, 6, 7, and 8 subtypes belong to group
III mGlu receptors. The ligands of the mGlu receptors were
shown to possess a variety of therapeutic properties,
including anxiolytic, antidepressant, and antipsychotic effi-
cacy (for reviews, see Chaki 2010; Palucha and Pilc 2007;
Schoepp 2001; Wierońska and Pilc 2009).
When it comes to antipsychotic therapy, animal studies
showed that allosteric modulators of mGlu5 receptors and
modulators of the II group of mGlu receptors can be
considered as putative antipsychotic agents (Benneyworth
et al. 2007; Cartmell et al. 1999; Galici et al. 2005, 2006).
The improvements of both positive and negative symptoms
of schizophrenia were also observed in a double-blind,
placebo-controlled clinical study, after the administration of
LY2140023, a prodrug of the selective group II mGlu
receptor agonist, LY404039 (Patil et al. 2007). However,
more recently, it was shown that LY2140023 and the active
control olanzapine did not separate from placebo (Kinon et
al. 2011). The role of mGluR5 has not been clinically
validated for psychosis.
The family of group III mGlu receptors is the largest one
and involves mGlu4, mGlu6, mGlu7, and mGlu8 subtypes.
Because ofthe lack ofthe brain-penetrating,selectively acting
agents until recently, it has been difficult to establish the
individual roles of the members of the group III mGlu family.
The experiments with non-selective orthosteric agonist of
group III mGlu receptors, ACPT-I (Acher et al. 1997),
demonstrated its anxiolytic, but not antidepressant, efficacy
(Stachowicz et al. 2009). The compound was also shown to
induce antipsychotic-like effects in animal models of positive
symptoms of the disease (Palucha-Poniewiera et al. 2008).
Recently, a newly synthesized group III mGlu receptor
agonist, LSP1-2111, preferentially activating mGlu4 sub-
types especially in low doses, because of the 30-fold higher
potency at that receptor subtype compared with the other
group III mGlu receptors expressed in the brain (Beurrier et
al. 2010), was shown to be a potent anxiolytic (Wierońska
et al. 2010) and antiparkinsonian (Beurrier et al. 2010), yet
not an antidepressant-like agent (Wierońska et al. 2010).
AMN082 was the first selective, positive allosteric modu-
lator of mGlu7 receptors (Mitsukawa et al. 2005) with
anxiolytic and antidepressant properties (Palucha et al.
2007; Stachowicz et al. 2008).
In the present study, both activators of group III mGlu
receptors mentioned above were investigated in animal
models of the positive symptoms of psychosis. We used
several procedures established earlier both in our studies
and by the other authors, such as MK-801- or
amphetamine-induced hyperactivity (Geyer and Ellenbroek
2003;P a łucha-Poniewiera et al. 2008), and DOI-induced
head twitches as the models with predictive validity of
psychosis and hallucination. Our results show that LSP1-
2111 induces potential antipsychotic-like effects in all of
the tests conducted, and the effect of the drug was
antagonized by group II/III receptor mixed antagonist,
LY341495. By contrast, AMN082 did not exhibit any
antipsychotic-like activity in our study, demonstrating
rather an enhancement of MK-801- or DOI-induced effects.
Additionally, we used mGlu7 knockout (KO) animals to
confirm that those effects of AMN082 were due to mGlu7
receptor stimulation. To summarize, our results suggest the
involvement of mGlu4, rather than the mGlu7 receptor, in
the antipsychotic-like action of mGlu group III receptor
agonists.
Materials and methods
Animals and housing Male Albino Swiss mice (20–25 g)
were used in all experimental procedures, except the
experiments where the mGlu7 KO animals were used.
mGlu7 receptor KO and wild type (WT) C57Bl/6J mice
(essentially described by Mitsukawa et al. 2005) were bred
at our institute. Heterozygous mice were obtained from
Novartis Pharma AG. The phenotypes of newborn mice
were analyzed by polymerase chain reaction, according to
Sansig et al. (2001). The animals were kept under a 12:12
light–dark cycle at a room temperature of 19–21°C with
free access to food and water. Each experimental group
consisted of 8–10 animals/dose, and the animals were used
only once in each test. All animals were experimentally
naive prior to testing. All the compounds used in our
studies were administered intraperitoneally (i.p.). For all the
experiments, the compounds were injected at a volume of
10 ml kg
−1. The experiments were performed by an
observer blind to the treatment and conducted according
to the procedures approved by the Animal Care and Use
Committee at the Institute of Pharmacology, Polish Acad-
emy of Sciences in Krakow.
Drugs LSP1-2111 was made in Dr. Francine Acher’s
laboratory and was dissolved in water; then the pH was
482 Psychopharmacology (2012) 220:481–494adjusted with NaOH to 7.0 before the stock solution was
dissolved in a saline buffer. AMN082 (Ascent Scientific,
Bristol, UK) and clozapine (Tocris Bioscience, Bristol, UK)
were dissolved in 0.5% Tylose (Sigma–Aldrich, St. Louis,
USA) in 0.9% NaCl (Sigma–Aldrich, St. Louis, USA).
MK-801, DOI, and d-amphetamine sulfate (Sigma–Aldrich,
St. Louis, USA) were dissolved in 0.9% NaCl, and
LY341495 was dissolved in 1% Tween 80. Haloperidol
(5 mg ml
−1 ampullae, Polfa, Warsaw, Poland) was
dispersed in 0.9% saline in order to obtain the concentration
of 0.25 mg kg
−1.
LSP1-2111 was administered 45 min before the experi-
ments, AMN082 and LY341495 60 min, haloperidol and
clozapine 30 min before the tests. The administration
schedule of the compounds was adapted from the other
studies, but also was based on our long-lasting experience
with the ligands used. Doses and routes of administration of
LSP1-2111 used in the present study were the same as those
used in our previous studies concerning the mechanisms of
anxiolytic and antidepressant action of that compound (see
Wierońska et al. 2010 and also Beurrier et al. 2010), and
the doses and timing of AMN082 administration were
matched according to Palucha et al. (2007), Stachowicz et
al. (2008), and Mitsukawa et al. (2005). Doses and timing
for LY341495 were based on the studies of Iijima et al.
(2007), Pałucha-Poniewiera et al. (2010), and Galici et al.
(2005, 2006).
Locomotor activity of habituated mice The locomotor
activity was recorded individually for each animal in
OPTO-M3 locomotor activity cages (Columbus Instrument)
linked online to a compatible PC. Each cage (13×23×
15 cm) was surrounded with an array of photocell beams.
Interruptions of these photobeams resulted in horizontal
activity defined as ambulation scores.
The locomotor activity of habituated mice was per-
formed as a control experiment for the studies on
hyperactivity induced by MK-801. The measurements were
performed as follows: mice were placed into actometers for
an acclimatization period of 30 min; then they were
administered with an i.p. injection of LSP1-2111,
AMN082 (5 and 6 mg kg
−1, respectively), or saline
(controls) and placed again into the same cages. From this
point on, the ambulation scores were measured every 10 for
80 min.
Spontaneous locomotor activity The procedure was per-
formed as a control study for amphetamine-induced
hyperactivity test. Mice were injected in their home cages
with LSP1-2111 or AMN082 (5 and 6 mg kg
−1, respec-
tively). Forty-five or 60 min later, respectively, they were
placed in the activity meters, and the locomotor activity
was recorded for 80 min every 10 min.
MK-801-induced hyperactivity The locomotor activity was
recorded for each animal in locomotor activity cages
(according to Rorick-Kehn et al. 2007), with small
modifications used in our previous studies (Pałucha-
Poniewiera et al. 2008; Wierońska et al. 2011). The mice
were placed individually into actometers for an acclimati-
zation period of 30 min; then they were administered i.p.
injections of the LSP1-2111 (0.3, 1, 2, and 5 mg kg
−1) and
AMN082 (3 and 6 mg kg
−1) and placed again in the same
cages. After 45 or 60 min, respectively, all of the mice were
given an i.p. administration of MK-801 in a dose of
0.3 mg kg
−1 and once again returned to the same cage.
From then on, the ambulation scores were counted every
10 min for 80 min. The total number of ambulation was
recorded at the end of an 80-min period of measure-
ment. All of the groups were compared with the MK-
801 control group. The experiment also included a
control group not treated with MK-801. The reference
compounds clozapine (10 mg kg
−1) and haloperidol
( 0 . 2 5m gk g
−1) were given 30 min before the MK-801
administration.
In the second part of the experiment, the highest
effective doses of LSP1-2111 were blocked by combined
mGluII/mGluIII antagonist LY341495. The drug was
administered in a dose of 1.5 mg kg
−1 60 min before the
test (15 min before LSP1-2111 administration).
Amphetamine-induced hyperactivity The activity of mice
was recorded following the method described in our
previous studies (Pałucha-Poniewiera et al. 2008; Wierońska
et al. 2011). LSP1-2111 or AMN082 was administered 45 or
60 min (respectively) before amphetamine (3 mg kg
−1)
injection. From then on, the ambulation scores were counted
every 10 min for 80 min. The total number of ambulation
was recorded at the end of an 80-min period of measure-
ment. All of the groups were compared with the amphet-
amine control group. The experiment also included a control
group not treated with amphetamine. The reference com-
pounds clozapine (10 mg kg
−1) and haloperidol
(0.25 mg kg
−1) were given 30 min before the amphetamine
administration.
In the second part of the experiment, the highest
effective doses of LSP1-2111 were blocked by combined
mGluII/mGluIII antagonist LY341495. The drug was
administered in a dose of 1.5 mg kg
−1 60 min before the
test (15 min before LSP1-2111 administration).
Locomotor activity of mGlu7 KO and WT animals Both
mGlu7 KO and WT animals were placed individually in
locomotor activity cages. After 30 min of habituation
period, the animals were injected with saline or AMN082
(6 mg kg
−1), and after an additional 60 min, the animals
were administered with MK-801 (0.3 mg kg
−1). Immedi-
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10 min for 80 min. The total number of ambulation was
recorded at the end of an 80-min period of measurement.
Head twitch test Theexperiment was performed accordingto
Pałucha-Poniewiera et al. (2008). In order to habituate mice
to the experimental environment, each animal was transferred
to a 12 (diameter)×20-cm (height) glass cage, lined with
sawdust, 30 min before the treatment. The head twitches of
the mice were induced by DOI (2.5 mg kg
−1,i . p ) .
Immediately after the treatment, the number of head twitches
was counted during a 20-min session. Haloperidol
(0.25 mg kg
−1) and clozapine (10 mg kg
−1) were adminis-
tered as reference compounds. LSP1-2111 (0.3, 1, 2, and
5m gk g
−1) and AMN082 (3 and 6 mg kg
−1)w e r eg i v e n4 5
and 60 min, respectively, prior to the DOI administration.
In the second part of the experiment, the highest
effective dose of LSP1-2111 was blocked by combined
mGluII/mGluIII antagonist LY341495. The drug was
administered in a dose of 1.5 mg kg
−1 60 min before the
test (15 min before LSP1-2111 administration).
Statistical analysis All the data are expressed as means ±
SEM and evaluated by repeated measure analysis of
variance (ANOVA), followed by Newman–Keuls post hoc
comparison (locomotor activity). Total locomotor activities
of mice injected with LSP1-2111 or AMN082 (insets) were
analyzed by one-way ANOVA followed by Dunnett’s test
or two-way ANOVA followed by Newman–Keuls. Total
activities of mGlu7 KO and mGlu7 WT mice were
analyzed with two-way ANOVA followed by Newman–
Keuls post hoc comparison. One-way ANOVA followed by
Dunnett’s post hoc test and two-way ANOVA followed by
Newman–Keuls post hoc were used to analyze the effects
of the drugs on DOI-induced head twitches. Graph Pad
Prism 4, version 5 (Graph Pad Software, San Diego, CA)
and STATISTICA version 9 were used to analyze the data.
Results
The effects of LSP1-2111 and AMN082 on locomotor
activity in mice habituated to activity meters Repeated
measure ANOVA revealed that in mice adapted to activity
meters for 30 min, the effect of LSP1-2111 (5 mg kg
−1) was
treatment [F(1.12)=11.44, p<0.05] and time dependent
[F(7.84)=14.59, p<0.0000]. No statistically significant effect
of time–dose interaction was observed [F(7.84)=1.6]
(Fig. 1a). Analysis of total locomotor activity (within the
entire 80-min experiment) showed that there were no
statistically significant differences between control and
LSP1-2111-treated animals (Fig. 1a, inset).
AMN082 (6 mg kg
−1) did not induce any treatment
effect [F(1.16)=1.3]; only the significant influence on time
was observed in animals habituated to locomotor activity
cages [F(7.112)=9.37, p<0.00001]. There was no significant
treatment × time interaction [F(7.112)=0.2] (Fig. 1b). Anal-
ysis of total locomotor activity (within the entire 80-min
experiment) showed that there were no statistically signif-
icant differences between control and AMN082-treated
animals (Fig. 1b, inset).
The effects of LSP1-2111 and AMN082 on spontaneous
locomotor activity in mice Repeated measure ANOVA
revealed that LSP1-2111 (5 mg kg
−1) induced a treatment-
[F(1.14)=6.5, p<0.02] and time-dependent effect [F(7.98)=
32.18, p<0.0000]. No statistically significant effect of
Fig. 1 Effect of LSP1-2111 (a) and AMN082 (b) on the locomotor
activity of mice habituated to activity meters. LSP1-2111 was given at
a dose of 5 mg kg
−1 45 min before the test, while AMN082 was given
60 min before the test in a dose of 6 mg kg
−1. Values expressed as
means ± SEM were evaluated by repeated measure ANOVA.
Locomotor activity was measured every 10 min over an 80-min time
session (insets the total activity of mice within the 80-min session was
analyzed by t test)
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Analysis of total locomotor activity (within the entire 80-
min experiment) showed that there were no statistically
significant differences between control and LSP1-2111-
treated animals (Fig. 2a, inset).
AMN082 (6 mg kg
−1) did not induce any effect on the
spontaneous locomotor activity [F(1.16)=1.53]. Only the effect
of time was shown to be statistically significant [F(7.112)=
30.7]. There was no statistically significant time–dose effect
[F(7.112)=0.5] (Fig. 2b). Analysis of total locomotor activity
(within the entire 80-min experiment) showed that there were
no statistically significant differences between control and
AMN082-treated animals (Fig. 2b, inset).
The effect of MK-801 on locomotor activity in mice MK-
801, in a dose of 0.3 mg kg
−1, produced a robust increase in
the ambulation scores within 80 min of the experimental
session [F(1.16)=60.5, p<0.000001], and time–dose interac-
tion was shown to be significant as well [F(7.96)=13.18, p<
0.0000] (Fig. 3a). Repeated measure ANOVA revealed that
the effects of reference compounds clozapine (10 mg kg
-1)
and haloperidol (0.25 mg kg
−1) were shown to be statistically
significant and inhibited the effect of MK-801 in a time-
dependent manner [F(7.98)=12.77, p<0.0000, and F(7.98)=
17.79, p<0.0000, respectively] (Fig. 3a).
The effects of LSP1-2111 on MK-801-induced hyperactivity
in mice LSP1-2111, in a dose of 0.3 mg kg
−1, had no effect
on the MK-801-induced hyperlocomotion. In a dose of
1m gk g
−1, the compound significantly abolished the MK-
801-induced effect [F(1.14)=41.12, p<0.0001]. Further-
more, there was a significant influence of time [F(7.98)=
12.9, p<0.0000] and significant time–dose interaction
[F(7.98)=5.6, p<0.00001]. Similarly, a significant reduction
of the MK-801 hyperactivity was observed after adminis-
tration of LSP1-2111 in the doses of 2 mg kg
−1 [F(1.14)=36,
p<0.0001] and 5 mg kg
−1 [F(1.14)=43.42, p<0.0001]. A
significant influence of time [F(7.98)=19.79, p<0.0001, and
F(7.98)=7.12, p<0.00001, respectively] and significant
time–dose interaction [F(7.98)=2.33, p<0.02, and F(7.98)=
7.12, p<0.00001, respectively] were also observed. Post
hoc analysis revealed that LSP1-2111 in all tested doses
decreased locomotor hyperactivity in five time points: 20,
30, 40, 50, and 60 min (Fig. 3b).
One-way ANOVA of total locomotor activity (within the
entire 80-min experiment) showed that LSP1-2111 in the
doses of 1-5 mg kg
-1 induced a significant reduction of
MK-801-induced hyperlocomotion [F(4.37)=14.15, p<
0.0001] (Fig. 3b, inset).
The effect of combined administration of LY341495 and
LSP1-2111 on MK-801-induced hyperactivity in mice The
effect of LY341495, a nonspecific group II/III mGlu
receptor antagonist, was not significant when administered
alone in a dose of 1.5 mg kg
−1, 60 min prior MK-801
[F(1.16)=0.008, p<0.9], and the interaction of time×
LY341495 was not significant either [F(7.112)=1.12, p<
0.35]. LY341495 given 15 min before LSP1-2111 reversed
the LSP1-2111-induced effect on MK-801 hyperlocomo-
tion. The effect of combined LSP1-2111/LY341495 admin-
istration was not significantly different from MK-801
[F(1.16)=1.23, p<0.28], and time×treatment interaction
was not significant either [F(7.112)=0.77, p<0.6] (Fig. 3c).
Two-way ANOVA of total locomotor activity (within the
entire 80-min experiment) showed significant inhibition of
LSP1-2111-induced effect by LY341495 [F(1.34)=4.21, p<
0.04] (Fig. 3c, inset).
The effect of AMN082 on the MK-801-induced hyper-
activity In contrast to LSP1-2111, mGlu7 allosteric modu-
Fig. 2 Effect of LSP1-2111 (a) and AMN082 (b) on the spontaneous
locomotor activity of mice. LSP1-2111 was given in a dose of
5m gk g
−1 45 min before the test, while AMN082 was given 60 min
before the test in a dose of 6 mg kg
−1. Values expressed as means ±
SEM were evaluated by repeated measure ANOVA. Locomotor
activity was measured every 10 min over an 80-min time session
(insets the total activity of mice within the 80-min session was
analyzed by one-way ANOVA)
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MK-801-induced hyperactivity when calculated with re-
peated measure ANOVA. The effect of a dose of 3 mg kg
−1
was statistically significant [F(1.14)=5.6, p<0.03], and there
was a significant effect of time [F(7.98)=19.55, p<0.00001]
and time–dose interaction [F(7.98)=11.39, p<0.000]. Similar
effects were observed for the dose of 6 mg kg
−1 for dose
[F(1.14)=79.39, p<0.00001], time [F(7.98)=37, p<0.000],
and time–dose interaction [F(7.98)=17.9, p<0.0001]. Post
hoc analyses revealed that AMN082 in a dose of 3 mg kg
−1
increased locomotor activity in one time point of 80 min,
and in a dose of 6 mg kg
−1, a statistically significant effect
was observed in four time points: 50, 60, 70, and 80 min
(Fig. 4a).
One-way ANOVA of total locomotor activity (within the
entire 80-min experiment) showed that AMN082 in doses
of 3 and 6 mg kg
−1 induced a significant enhancement of
MK-801 hyperlocomotion [F(2.20)=14.86; p<0.001 and p<
0.0001] (Fig. 4a, inset).
The effect of MK-801 on the locomotor activity in mGlu7
KO and WT mice After 90 min of habituation period
(30 min of habituation and 60 min after saline injection),
there was no statistical difference between locomotor
activity of KO and WT animals [F(1.10)=2.9]. MK-801
(0.3 mg kg
−1) induced a robust increase of locomotor
activity of both KO and WT mice, and the effect was dose
dependent [F(1.10)=536, p<0.0000, and F(1.10)=222, p<
0.0000, respectively], time dependent [F(7.70)=4.59, p<
0.0002, and F(7.70)=2.5, p<0.02, respectively], and time–
dosedependent [F(7.70)=7.7,p<0.00001,andF(7.70)=6.7,p<
0.0001, respectively]. There were no statistically significant
differences between KO and WT animals (Fig. 4b, c).
The effect of AMN082 on MK-801-induced hyperactivity in
mGlu7 KO and WT mice AMN082 (6 mg kg
−1) induced a
decrease of locomotor activity of WTanimals [F(1.10)=5.86,
p<0.03], the effect of the compound was time dependent
[F(7.70)=12, p<0.000], and there was time–dose interaction
[F(7.70)=2.33, p<0.03]. Post hoc analysis revealed that
AMN082 decreased locomotor activity of WT animals in
one time point, after 10 min (Fig. 4b). The drug had no
effect on KO animals [F(1.10)=0.99] (Fig 4c).
When AMN082 (6 mg kg
−1) was given 60 min prior
MK-801 (0.3 mg kg
−1) administration, an enhancement of
Fig. 3 Effectofstandard antipsychotic drugs,haloperidol, andclozapine
on the MK-801-induced hyperactivity in mice (a). Clozapine and
haloperidol were given 30 min before the MK-801 administration.
LSP1-2111 abolished MK-801-induced effect when administered
45 min before MK-801 administration (b). LY341495 abolished the
effect of the highest dose of LSP1-2111 (5 mg kg
−1) when given 15 min
prior LSP1-2111 (c). Locomotor activity was monitored every 10 min
over an 80-min session immediately following an injection of
psychostimulant agent. The data are presented as means ± SEM and
analyzed by repeated measure ANOVA (inset the total activity of mice
within the 80-min session was analyzed by one-way ANOVA [a, b]o r
two-way ANOVA [c])
#p<0.001 vs. control group and *** p<0.001,
**p<0.01, and *p<0.05 vs. MK-801-treated group
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[F(1.10)=17.45, p<0.001]; the effect was time dependent
[F(7.70)=17.07, p<0.0000], and time–dose interaction was
also significant [F(7.70)=2.7, p<0.01]. Post hoc analysis
revealed that the effect of AMN082 was statistically
significant in three time points: 40, 50, and 60 min
(Fig. 7a). Such an effect was not observed in KO animals,
when AMN082 was given prior MK-801 administration
[F(1.10)=2.8] (Fig. 4c).
Two-way ANOVA of total locomotor activity (within the
entire 80-min experiment) showed that AMN082 in a dose
of 6 mg kg
−1 induced a significant enhancement of MK-
801 hyperlocomotion in WT mice [F(1.28)=12.06, p<0.001]
(Fig. 4b, inset). Such an effect was not observed in KO
mice (Fig. 4c, inset).
The effect of amphetamine on locomotor activity in
mice Amphetamine, in a dose of 3 mg kg
−1, produced a
robust increase in the ambulation scores within 80 min of
the experimental session [F(1.16)=62.05, p<0.000001], and
time–dose interaction was significant, as well [F(7.112)=8.7,
p<0.0000] (Fig. 5a). Repeated measure ANOVA revealed
that the effects of reference compounds clozapine
(10 mg kg
−1) and haloperidol (0.25 mg kg
−1) were shown
to be statistically significant and inhibited the effect of
amphetamine in a time-dependent manner [F(7.119)=12.27,
p<0.0000, and F(7.16)=17.79, p<0.0000, respectively]
(Fig. 5a).
The effect of LSP1-2111 on the amphetamine-induced
hyperactivity Repeated measure ANOVA revealed that
LSP1-2111, in a dose of 0.3 mg kg
−1, did not diminish
hyperactivity of mice. However, in a dose of 1 mg kg
−1,i t
significantly abolished the amphetamine-induced effect
[F(1.14)=12.1, p<0.01]. Furthermore, there was a significant
influence of time [F(7.98)=28.52, p<0.0000] and time–dose
interaction [F(7.98)=7.9, p<0.00001]. A similar abolishment
of the amphetamine hyperactivity was observed after admin-
istration of the LSP1-2111 in doses of 2 mg kg
−1 [F(1.14)=
11.3, p<0.05] and 5 mg kg
−1 [F(1.14)=29.19, p<0.0001]. A
significant influence of time [F(7.98)=26.5, p<0.0001, and
F(7.98)=18.9, p<0.00001, respectively] and time–dose inter-
action [F(7.98)=3.5, p<0.01, and F(7.98)=4.47, p<0.0005,
respectively] were also observed. Post hoc analysis revealed
that LSP1-2111 in the dose of 1 mg kg
−1 decreased
locomotor hyperactivity in two time points: 40 and 50 min
Fig. 4 Effect of AMN082 on the MK-801-induced hyperactivity test
in Albino Swiss mice (a). AMN082 was given 60 min before the MK-
801 administration. The data are presented as means ± SEM and
analyzed by repeated measure ANOVA (inset the total activity of mice
within the 80-min session was analyzed by one-way ANOVA) . Effect
of AMN082 on the MK-801-induced locomotor activity of C57Bl/6J
wild type mice (b) and mGlu7 KO animals (c). AMN082 was given
60 min before the MK-801 administration. Locomotor activity was
monitored every 10 min over an 80-min session immediately
following an injection of MK-801. The data are presented as means
± SEM and analyzed by repeated measure ANOVA (inset the total
activity of mice within the 80-min session was analyzed by two-way
ANOVA)
#p<0.001 vs. control group and ***p<0.001, **p<0.01 and
*p<0.05 vs. MK-801-treated group
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−1 decreased locomotor
activity in three time points of 30, 40, and 50 min, and the
d o s eo f5m gk g
−1 abolished amphetamine-induced effect in
six time points: 10, 20, 30, 40, 50, and 60 min (Fig. 5b).
One-way ANOVA of total locomotor activity (within the
entire 80-min experiment) showed that LSP1-2111 induced
a significant, dose-dependent attenuation of amphetamine-
induced hyperlocomotion [F(4.36)=13.27, p<0.001]
(Fig. 5b, inset).
The effect of combined administration of LY341495 and
LSP1-2111 on amphetamine-induced hyperactivity in
mice The effect of LY341495 was not significant when
administered in a dose of 1.5 mg kg
−1, 60 min before the
amphetamine [F(1.13)=0.14, p<0.7], and LY341495×time
interaction was also not significant [F(7.91)=1.7, p<0.1].
LY341495 given 15 min before LSP1-2111 reversed the
LSP1-2111-induced effect on amphetamine hyperlocomotion.
The effect of combined LSP1-2111/LY341495 administration
was not significantly different from amphetamine. The effect
of treatment [F(1.14)=0.11, p<0.7] and treatment×time
interaction [F(7.98)=0.4, p<0.8] were not significant (Fig. 5c).
Two-way ANOVA of total locomotor activity (within the
entire 80-min experiment) showed significant inhibition of
LSP1-2111-induced effect by LY341495 [F(1.31)=6.8, p<
0.01] (Fig. 5c, inset).
The effect of AMN082 on the amphetamine-induced hyper-
activity In contrast to mGlu4 agonist, the administration of
mGlu7 allosteric modulator AMN082 had no influence on
the amphetamine-induced hyperactivity when calculated
with repeated measure ANOVA. There was no dose or
time–dose effect of the compound when calculated for the
dose of 3 mg kg
-1 [F(1.14)=4.3, F(7.98)=0.5] and for the dose
of 6 mg kg
−1 [F(1.14)=0.7, F(7.98)=0.9] (Fig. 6).
The effect of LSP1-2111 on DOI-induced head twitches in
mice Both reference compounds used, haloperidol and
clozapine, significantly reduced the number of head
twitches (p<0.001) (Fig. 7a). LSP1-2111, administered i.p.
in the doses 1, 2, and 5 mg kg
−1, produced a significant,
dose-dependent decrease in the number of DOI-induced
head twitches in mice (approximately 68%, 39%, and
29% of the control, respectively, Fig. 7b)[ F(4.35)=13, p<0.05
and p<0.001]. LY341495 given 60 min before DOI
induced significant attenuation of LSP1-2111-induced
effect [F(1.25)=14.17, p<0.0009] (Fig. 7c).
The effect of AMN082 on DOI-induced head twitches in
Albino Swiss and C57Bl/6J mGlu7 KO and WT
Fig. 5 Effect of standard antipsychotic drugs, haloperidol and
clozapine, on the amphetamine-induced hyperactivity in mice (a).
Clozapine and haloperidol were given 30 min before the amphetamine
administration. LSP1-2111 dose dependently abolished amphetamine
hyperlocomotion when administered 45 min before amphetamine (b).
LY341495 abolished the effect of the highest dose of LSP1-2111
(5 mg kg
−1) when given 15 min prior LSP1-2111 (c). Locomotor
activity was monitored every 10 min over an 80-min session
immediately following an injection of psychostimulant agent. The
data are presented as means ± SEM and analyzed by repeated measure
ANOVA (inset the total activity of mice within the 80 min session was
analyzed by one-way ANOVA [a, b] or two-way ANOVA [c])
#p<
0.001 vs. control group and *** p<0.001, **p<0.01, and *p<0.05 vs.
amphetamine-treated group
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−1, did not
antagonize the DOI-induced effect; the highest dose of
6m gk g
−1 significantly enhanced the effect of DOI [F(2.17)=
8.11, p<0.01] (Fig. 8a). The experiments with mGlu7
knockout animals revealed that the lack of the receptor
resulted in the decreased number of DOI-induced head
twitches by approximately 61% of the control (p<0.01).
AMN082, given in the highest dose of 6 mg kg
−1, enhanced
the effect of DOI in WTanimals but did not evoke any effect
in mGlu7 KO mice (Fig. 8b).
Discussion
In the present study, we focused on the antipsychotic-like
activity of LSP1-2111, a recently synthesized group III
mGlu receptor orthosteric agonist, preferentially activating
mGlu4 subtype especially in low doses, and AMN082, a
selective positive allosteric modulator of the mGlu7
receptor (Mitsukawa et al. 2005).
LSP1-2111, typically to other orthosteric agonists,
competes with glutamate binding to its binding site on the
receptor. In contrast, AMN082 binds the allosteric binding
site located within the transmembrane domain and enhances
the affinity of glutamate to the glutamate-binding site, as
the other positive allosteric modulators do.
We used MK-801- and amphetamine-induced hyper-
locomotion, which represents models to test the anti-
psychotic activity of drugs, mainly with respect to the
positive symptoms of the disease (Geyer and Ellenbroek
2003).
In our previous study, we demonstrated that group III
non-selective orthosteric agonist ACPT-I diminished the
MK-801-induced hyperlocomotion with a tendency for the
U-shaped effect. Here, LSP1-2111 inhibited MK-801-
induced hyperlocomotion with similar efficacy in all three
investigated doses, while a dose-dependent inhibition of
amphetamine-induced hyperlocomotion by the compound
was observed. In this case, the drug was more effective than
the previously used ACPT-I (having a similar affinity to the
mGlu4 and mGlu8 receptors) (Table 1), which inhibited
Fig. 7 The suppression of DOI-induced head twitches by the
reference compounds haloperidol and clozapine (a), and LSP1-2111
(b). The effect of the highest dose of LSP1-2111 was partially
abolished by LY341495 (c). The values represent the number of head
twitches (mean ± SEM) during a 20-min test. The data are presented
as means ± SEM. ***p<0.001, **p<0.01, and *p<0.05 vs. DOI-
treated group;
#p<0.05 vs. LSP1-2111-treated group
Fig. 6 Effect of AMN082 on the amphetamine-induced hyperactivity
test. AMN082 was given 60 min before amphetamine administration.
Locomotor activity was monitored every 10 min over an 80-min
session immediately following an injection of psychostimulant agent.
The data are presented as means ± SEM and analyzed by repeated
measure ANOVA (inset the total activity of mice within the 80-min
session was analyzed by one-way ANOVA)
#p<0.001 vs. control
group
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investigated dose (100 mg kg
−1).
The second investigated ligand, AMN082, did not
influence amphetamine-induced hyperlocomotion. More-
over, the enhancement of MK-801-induced hyperactivity
was observed after drug administration.
To further investigate the potential antipsychotic-like
activity of LSP1-2111 and AMN082, we decided to use a
behavioral model of hallucinations, which are known to be
an important aspect of schizophrenia in humans.
Hallucinogenic-like activity can be achieved via stimulation
of serotonergic receptors both in mice and in humans
(Tadano et al. 1986). Administration of the 5-HT2A receptor
agonist DOI induces a characteristic behavioral effect
consisting of twitches of heads in mice (Darmani et al.
1990), attenuated by typical and atypical neuroleptics
(Darmani et al. 1990). In the previous studies, it was
shown that mGlu2/3 receptoragonists, LY354740 or
LY379268 (Marek et al. 2000;K łodzinska et al. 2002),
and mGlu4/8 receptor agonist, ACPT-I (Pałucha-Ponie-
wiera et al. 2008) dose dependently inhibited DOI-induced
head twitches in mice. In the present study, LSP1-2111
inhibited DOI-induced head twitches in the dose-
dependent, monophasic manner, resembling the effect of
the previously used group II/III mGlu receptor ligands.
The main advantage of LSP1-2111, a newly synthesized
compound, is a 30-fold higher potency at the mGlu4
receptor compared with the other group III mGlu receptors
expressed in the brain, and comparing to L-AP4 or ACPT-I,
it better discriminates between the mGlu4 and mGlu7/
mGlu8 receptors (Table 1, Beurrier et al. 2010) especially
in low doses. The compound also has no appreciable
affinity at over 70 drug targets (Cerep assay) at concen-
trations up to 10 μM. The present results with AMN082
and the studies of Robbins et al. (2007), showing that the
selective mGlu8 agonist (S)-3,4-DCPG did not exert
antipsychotic-like activity in rodents, may support the
speculation that the antipsychotic-like action of LSP1-
2111 is due to simulation of mGlu4 receptors. However,
its action at mGlu8 receptors cannot be excluded at the
moment. The pharmacokinetic assay should be conducted
to look at its brain concentrations and to verify its ability to
stimulate mGlu4, but not mGlu8 receptors in the doses used
in our studies. The use of mGlu4 receptor KO mice could
help to solve this problem, but as we were unable to obtain
them, the non-selective antagonist of mGlu receptors,
LY341495 (Kingston et al. 1998), was applied. LY341495
blocked the action of LSP1-2111 in all three models used,
confirming that the action of LSP1-2111 is due to
stimulation of mGlu receptors, and while no discrimination
between selected receptor subtypes is possible with that
compound, the results further indicate that no “off target”
mechanisms are involved in the antipsychotic-like action of
LSP1-2111.
The fundamental mechanism of the mGlu-mediated
antipsychotic-like activity of LSP1-2111, exerted perhaps
via stimulation of mGlu receptors, may be related to
Table 1 Activity of ACPT-1 and LSP1-2111 on mGlu receptors
EC50 (μm)
ACPT-I LSP1-2111
Group I – NE
Group II – NE
Group III
mGlu4 1.7±0.23 2.2±0.27
mGlu6 10.60±3.38 1.7±0.13
mGlu7 280.5±84.5 52.87±20.66
mGlu8 5.13±0.84 65.97±11.81
EC50 values are means ± SEM
NE compound has no agonist or antagonist activity at 100 μm
(Beurrier et al. 2010)
Fig. 8 The effect of AMN082 on DOI-induced head twitches in mice
(a) and the effect of DOI on the mGlu7 KO C57Bl/6J mice during a
20-min session and the lack of AMN082 effect after administration to
mGlu7 KO animals (b). AMN082 was given in the dose of 6 mg kg
−1,
60 min before DOI administration. Values represent the mean number
of head twitches ±SEM. **p<0.01 and *p<0.05 vs. DOI-treated
group,
#p<0.01 vs. WT animals
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pathological state, here evoked by the administration of
MK-801, amphetamine, or DOI. As the mGlu4 receptors,
localized on glutamatergic terminals, are strongly involved
in the regulation of glutamate release (Corti et al. 2002), it
is very likely that the mechanism of action of LSP1-2111
could be based presumably on the reduction of the increased
extracellular glutamate level, responsible for the behavioral
effects observed after MK-801 administration (Carlsson et al.
2001;C o y l e2006;D a l l ’Olio et al. 2000;L i n d s l e ye ta l .
2006). The strong support for this hypothesis arises from the
studies on mGlu2/3 receptor agonists, where antipsychotic-
like activity was suggested in both preclinical (Fell et al.
2008;K a n u m ae ta l .2010;M o n ne ta l .2007) and clinical
studies (Patil et al. 2007; for review, see Chaki 2010).
On the other hand, the effect of LSP1-2111 could be
achieved via activation of mGlu4 heteroreceptors expressed
on dopaminergic terminals in the nucleus accumbens shell,
the structure purportedly responsible for psychostimulant-
induced hyperlocomotion (Costall et al. 1979). The in-
creased dopaminergic activity is not only the fundamental
mechanism of amphetamine action, but partially can be
involved in MK-801-induced effects (Seeman and Lasaga
2005). Therefore, the compounds that counteracted the
increased excitability of the brain due to an enhanced
glutamate/dopamine efflux could potentially be considered
as effective in ameliorating symptoms relative to schizo-
phrenia (Conn et al. 2009). Unfortunately, as the immuno-
histochemical data concerning the expression of the
receptor at the dopaminergic terminals are lacking, the
hypothesis is rather speculative at this moment. Some
indirect evidence supporting the hypothesis could be
based on the studies concerning the agonists of the
mGlu2/3 receptors with proven antipsychotic-like effi-
cacy (Galici et al. 2005, 2006), which reduced dopamine
release into the nucleus accumbens shell (Cartmell and
Schoepp 2000; Greenslade and Mitchell 2004), probably
through the activation of presynaptically expressed
mGlu2/3 heteroreceptors.
Concerning the rodent model of hallucinations, it is
probable that the presynaptic inhibition of the glutamate
release via activation of mGlu4 autoreceptors may be
considered as the mechanism of inhibition of the DOI-
induced behavioral effect by LSP1-2111. The activation of
5-HT2A receptors in the prefrontal cortex by DOI is
postulated to enhance the glutamate release responsible
for hallucinogenic-like effect (see Aghajanian and Marek
2000). Electrophysiological studies performed earlier
with non-selective ligands of group III mGlu receptors
are in agreement with such a hypothesis, as ACPT-I, L-
SOP and 1S, 3S-ACPD inhibited serotonin- or DOI-
induced EPSPs (Aghajanian and Marek 2000;P a łucha-
Poniewiera et al. 2008).
Considering the mechanism of antipsychotic-like activity
mediated by the group III mGlu receptor ligands, it cannot be
overlooked that the second investigated ligand, AMN082, a
positive allostericmodulator ofmGlu7 receptors,did not have
any effect on the amphetamine-induced locomotion, and it
produced even an enhancement of MK-801-induced hyper-
locomotionandanincreasednumberoftheDOI-inducedhead
twitches. The results indicate the lack of antipsychotic action
and rather the existence of a pro-psychotic activity of
AMN082 in animal models.
However, recent studies have suggested that the activity
of AMN082 is complex and can be highly context specific
with effects observed in some but not in other systems,
based on specific signaling pathway engagement. AMN082
does not produce mobilization of calcium downstream of
mGluR7 in a cell line coexpressing the receptor with a
promiscuous G protein (Suzuki et al. 2007); it does not
produce mGluR7-mediated activation of GIRK potassium
channels in human embryonic kidney cells nor activate
mGluR7 at the Shaffer collateral-CA1 synapse (Ayala et al.
2008). Therefore, the negative findings with AMN082 in
the amphetamine model as evidence that mGlu7 receptor is
not involved in modulation of dopaminergic functions
should be interpreted with caution. Also recently, it was shown
that the in vivo actions of AMN082 may involve other (e.g.,
monoaminergic) mechanisms in addition to mGluR7 stimula-
tion (Sukoff Rizzo et al. 2011); hence, we conducted
additional experiments with mGlu7 KO and WT animals to
establish if those AMN082-induced effects were caused by
the direct stimulation of the receptor. The stimulatory effect of
MK-801 on locomotor activity was more or less comparable
both in C57Bl/6J WT and in mGlu7 KO mice. However, the
enhancement of MK-801-induced hyperlocomotion by
AMN082 administration observed in WT animals was absent
in mGlu7 KO mice; similar results were obtained in the head
twitch test. Interestingly, the attenuation of hallucinogenic-
like effect of DOI in Glu7 KO mice was observed, suggesting
that the mGlu7 depletion may be considered as the effect
opposite to the agonistic action of AMN082.
The results obtained with the use of mGlu7 receptor KO
animals clearly indicated that the observed effects of
AMN082 on MK-801- and DOI-induced effects were due
to stimulation of mGlu7 receptors and not to some
unspecific or secondary actions of the compound. Our
previous experiments showing that the anxiolytic and
antidepressant activity of AMN082 (Palucha et al. 2007;
Stachowicz et al. 2008) were also lacking in mGlu7 KO
animals support this line of thinking.
The results obtained in the present study are, however,
rather surprising as all subtypes of mGlu receptors are
generally believed to be expressed presynaptically and
engaged in the regulation of neurotransmitter release
(Schoepp 2001). However, the different pattern of action
Psychopharmacology (2012) 220:481–494 491of AMN082 and LSP1-2111 indicates the obvious dissim-
ilarity of their physiological function and their ability in the
restoration of the excitatory–inhibitory balance disrupted in
a pathological state (Linden and Schoepp 2006). The
mGlu7 receptor, localized presynaptically preferentially on
GABAergic interneurons (Dalezios et al. 2002; Somogyi et
al. 2003), inhibits GABAergic neurotransmission under
activation, and the effect may contribute to the enhance-
ment of excitation in the CNS. The confirmation of that
speculation arises from the studies by Li et al. showing a
decreased extracellular GABA release accompanied by an
increased glutamate efflux in the nucleus accumbens after
AMN082 administration (Li et al. 2008). Such data are in
line with the pro-psychotic action of AMN082. By contrast,
activation of mGlu4 receptors, distributed either on the
glutamatergic and GABAergic nerve terminals, influences
the release of both neurotransmitters (Benítez et al. 2000;
Corti et al. 2002). As such, it can be speculated that the
final result of the stimulation of the mGlu4 receptor is a
decreased glutamatergic function via mGlu4 autoreceptors
and inhibition of the dopamine release via mGlu4 hetero-
receptors (what is to be investigated).
These studies suggest that mGlu4 receptor, rather than
mGlu7 receptor,may be the primary target of the antipsychotic-
like efficacy of the group III mGlu receptor agonists. It is
important to mention that the selectivity of both drugs,
especially LSP1-2111, is based on in vitro data only, and there
isnoguaranteethatthistranslatestoasimilarinvivoselectivity.
Additional pharmacokinetics studies would be needed to show
that the free brain levels are consistent with the levels that
activate only mGlu4 subtype. However, based on the present
results with AMN082 and those of Robbins et al. with DHPG
(Robbins et al. 2007), it is very likely that the preferential
stimulation of mGlu4 receptor by LSP1-2111 is responsible
for the behavioral effects observed in the present study.
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